Mechanisms of bone metastasis in prostate cancer: clinical implications

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 22, Issue 2, 2008, Pages 341-355

  Msaouel, Pavlos ^a   Pissimissis, Nikos ^a   Halapas, Antonios ^a   Koutsilieris, Michael ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

bone metastasis; cancer therapy; micrometastasis; prostate cancer; survival factors

Indexed keywords

ANGIOPEPTIN; ANTIANDROGEN; DEXAMETHASONE; DIETHYLSTILBESTROL; ESTRAMUSTINE; ETOPOSIDE; GONADORELIN AGONIST; LEUPRORELIN; OCTREOTIDE; OSTEOPROTEGERIN; PROSTATE SPECIFIC ANTIGEN; SOMATOSTATIN DERIVATIVE; TRIPTORELIN; ZOLEDRONIC ACID;

ADVANCED CANCER; BLOOD PRESSURE MEASUREMENT; BLOOD TOXICITY; BONE BIOPSY; BONE METASTASIS; BONE RADIOGRAPHY; BONE SCINTISCANNING; BRACHYTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL INTERACTION; CHOLESTASIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DRUG EFFICACY; DRUG MECHANISM; EXTERNAL BEAM RADIOTHERAPY; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HUMAN; MICROENVIRONMENT; MONOTHERAPY; ORCHIECTOMY; OSTEOCLAST; OSTEOLYSIS; PROSTATE CANCER; PROSTATECTOMY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIDE EFFECT; TRANSRECTAL ULTRASONOGRAPHY;

APOPTOSIS REGULATORY PROTEINS; BONE NEOPLASMS; BONE RESORPTION; CELL MOVEMENT; DEXAMETHASONE; DRUG DELIVERY SYSTEMS; HUMANS; MALE; MODELS, BIOLOGICAL; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; SOMATOMEDINS; SOMATOSTATIN;

EID: 42949179038     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2008.01.011     Document Type: Review

References (76)

1. Koutsilieris M. Osteoblastic metastasis in advanced prostate cancer. Anticancer Research 13 (1993) 443-449
2. Koutsilieris M. Skeletal metastases in advanced prostate cancer: cell biology and therapy. Critical Reviews in Oncology/Hematology 18 (1995) 51-64
3. Koutsilieris M., Sourla A., Pelletier G., et al. Three-dimensional type I collagen gel system for the study of osteoblastic metastases produced by metastatic prostate cancer. Journal of Bone and Mineral Research 9 (1994) 1823-1832
4. Sourla A., Doillon C., and Koutsilieris M. Three-dimensional type I collagen gel system containing MG-63 osteoblasts-like cells as a model for studying local bone reaction caused by metastatic cancer cells. Anticancer Research 16 (1996) 2773-2780
5. Bubendorf L., Schopfer A., Wagner U., et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Human Pathology 31 (2000) 578-583
6. Roudier M.P., True L.D., Higano C.S., et al. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Human Pathology 34 (2003) 646-653
7. Koutsilieris M., and Tolis G. Gonadotropin-releasing hormone agonistic analogues in the treatment of advanced prostatic carcinoma. The Prostate 4 (1983) 569-577
8. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. The Journal of the American Medical Association 281 (1999) 1591-1597
9. Tolis G., Faure N., Koutsilieris M., et al. Suppression of testicular steroidogenesis by the GnRH agonistic analogue Buserelin (HOE-766) in patients with prostatic cancer: studies in relation to dose and route of administration. Journal of Steroid Biochemistry 19 (1983) 995-998
10. Dupont A., Gomez J.L., Cusan L., et al. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. The Journal of Urology 150 (1993) 908-913
11. Koutsilieris M., Laroche B., Thabet M., et al. The assessment of disease aggressivity in stage D2 prostate cancer patients. [review]. Anticancer Research 10 (1990) 333-336
12. Reyes-Moreno C., Sourla A., Choki I., et al. Osteoblast-derived survival factors protect PC-3 human prostate cancer cells from adriamycin apoptosis. Urology 52 (1998) 341-347
13. Charlesworth P.J., and Harris A.L. Mechanisms of disease: angiogenesis in urologic malignancies. Nature Clinical Practice 3 (2006) 157-169
14. Dimitriadou V., and Koutsilieris M. Mast cell-tumor cell interactions: for or against tumour growth and metastasis?. Anticancer Research 17 (1997) 1541-1549
15. Dimitriadou V., Mecheri S., Koutsilieris M., et al. Expression of functional major histocompatibility complex class II molecules on HMC-1 human mast cells. Journal of Leukocyte Biology 64 (1998) 791-799
16. Janvier R., Sourla A., Koutsilieris M., et al. Stromal fibroblasts are required for PC-3 human prostate cancer cells to produce capillary-like formation of endothelial cells in a three-dimensional co-culture system. Anticancer Research 17 (1997) 1551-1557
17. Rennebeck G., Martelli M., and Kyprianou N. Anoikis and survival connections in the tumor microenvironment: is there a role in prostate cancer metastasis?. Cancer Research 65 (2005) 11230-11235
18. Rosol T.J., Tannehill-Gregg S.H., LeRoy B.E., et al. Animal models of bone metastasis. Cancer 97 (2003) 748-757
19. Chay C.H., Cooper C.R., Gendernalik J.D., et al. A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. Urology 60 (2002) 760-765
20. Walz D.A., and Fenton J.W. The role of thrombin in tumor cell metastasis. Invasion & Metastasis 14 (1994) 303-308
21. Wu J.D., Higgins L.M., Steinle A., et al. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. The Journal of Clinical Investigation 114 (2004) 560-568
22. Blades R.A., Keating P.J., McWilliam L.J., et al. Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 46 (1995) 681-686 [discussion: 6-7]
23. Batson O.V. The vertebral system of veins as a means for cancer dissemination. Progress in Clinical Cancer 3 (1967) 1-18
24. Ghossein R.A., Scher H.I., Gerald W.L., et al. Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. Journal of Clinical Oncology 13 (1995) 1195-1200
25. Karamanolakis D., Bogdanos J., Sourla A., et al. Molecular evidence-based use of bone resorption-targeted therapy in prostate cancer patients at high risk for bone involvement. Molecular Medicine (Cambridge, Mass.) 8 (2002) 667-675
26. Koutsilieris M., Lembessis P., Luu-The V., et al. Repetitive and site-specific molecular staging of prostate cancer using nested reverse transcriptase polymerase chain reaction for prostate specific antigen and prostate specific membrane antigen. Clinical & Experimental Metastasis 17 (1999) 823-830
27. Mitsiades C.S., Lembessis P., Sourla A., et al. Molecular staging by RT-PCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer. Clinical & Experimental Metastasis 21 (2004) 495-505
28. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Reviews 8 (1989) 98-101
29. Lehr J.E., and Pienta K.J. Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. Journal of the National Cancer Institute 90 (1998) 118-123
30. Honn K.V., and Tang D.G. Adhesion molecules and tumor cell interaction with endothelium and subendothelial matrix. Cancer Metastasis Reviews 11 (1992) 353-375
31. Bogdanos J., Karamanolakis D., Tenta R., et al. Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton. Endocrine-Related Cancer 10 (2003) 279-289
32. Koutsilieris M., Bogdanos J., Milathianakis C., et al. Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach. Expert Opinion on Investigational Drugs 15 (2006) 795-804
33. Koutsilieris M., Mitsiades C., and Sourla A. Insulin-like growth factor I and urokinase-type plasminogen activator bioregulation system as a survival mechanism of prostate cancer cells in osteoblastic metastases: development of anti-survival factor therapy for hormone-refractory prostate cancer. Molecular Medicine (Cambridge, Mass.) 6 (2000) 251-267
34. Koutsilieris M., Tzanela M., and Dimopoulos T. Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone-refractory prostate cancer: case report. The Prostate 38 (1999) 313-316
35. Hsu H., Lacey D.L., Dunstan C.R., et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proceedings of the National Academy of Sciences of the United States of America 96 (1999) 3540-3545
36. Holen I., Croucher P.I., Hamdy F.C., et al. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Research 62 (2002) 1619-1623
37. Mori K., Le Goff B., Charrier C., et al. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process. Bone 40 (2007) 981-990
38. Fizazi K., Yang J., Peleg S., et al. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clinical Cancer Research 9 (2003) 2587-2597
39. Koutsilieris M., Frenette G., Lazure C., et al. Urokinase-type plasminogen activator: a paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases. Anticancer Research 13 (1993) 481-486
40. Koutsilieris M., Rabbani S.A., Bennett H.P., et al. Characteristics of prostate-derived growth factors for cells of the osteoblast phenotype. The Journal of Clinical Investigation 80 (1987) 941-946
41. Polychronakos C., Janthly U., Lehoux J.G., et al. Mitogenic effects of insulin and insulin-like growth factors on PA-III rat prostate adenocarcinoma cells: characterization of the receptors involved. The Prostate 19 (1991) 313-321
42. Zhang J., Dai J., Qi Y., et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. The Journal of Clinical Investigation 107 (2001) 1235-1244
43. Koutsilieris M., Rabbani S.A., and Goltzman D. Selective osteoblast mitogens can be extracted from prostatic tissue. The Prostate 9 (1986) 109-115
44. Koutsilieris M., Rabbani S.A., and Goltzman D. Effects of human prostatic mitogens on rat bone cells and fibroblasts. The Journal of Endocrinology 115 (1987) 447-454
45. Mitsiades C., Bogdanos J., Karamanolakis D., et al. Bone microenvironment participation in the development of androgen ablation in prostate cancer patients with bone metastases: clinical application of an anti-survival factor therapy. In: Labrie F., and Koutsilieris M. (Eds). Prostate cancer: understanding the pathophysiology and re-designing a therapeutic approach (2004), Paschalidis Medical Publications, Athens 109-134
46. Nelson J.B., Hedican S.P., George D.J., et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nature Medicine 1 (1995) 944-949
47. Koutsilieris M., and Polychronakos C. Proteinolytic activity against IGF-binding proteins involved in the paracrine interactions between prostate adenocarcinoma cells and osteoblasts. Anticancer Research 12 (1992) 905-910
48. Edlund M., Sung S.Y., and Chung L.W. Modulation of prostate cancer growth in bone microenvironments. Journal of Cellular Biochemistry 91 (2004) 686-705
49. Tenta R., Sourla A., Lembessis P., et al. Bone microenvironment-related growth factors, zoledronic acid and dexamethasone differentially modulate PTHrP expression in PC-3 prostate cancer cells. Hormone and metabolic research. Hormon- und Stoffwechselforschung. Hormones et métabolisme 37 (2005) 593-601
50. Mitsiades C.S., and Koutsilieris M. Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer. Expert Opinion on Investigational Drugs 10 (2001) 1099-1115
51. Reyes-Moreno C., Frenette G., Boulanger J., et al. Mediation of glucocorticoid receptor function by transforming growth factor beta I expression in human PC-3 prostate cancer cells. The Prostate 26 (1995) 260-269
52. Labrie F., Dupont A., Cusan L., et al. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clinical and Investigative Medicine 16 (1993) 499-509
53. Labrie F., Dupont A., Suburu R., et al. Optimized strategy for detection of early stage, curable prostate cancer: role of prescreening with prostate-specific antigen. Clinical and Investigative Medicine 16 (1993) 425-439
54. Blute M.L., Bergstralh E.J., Iocca A., et al. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. The Journal of Urology 165 (2001) 119-125
55. Shipley W.U., Thames H.D., Sandler H.M., et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. The Journal of the American Medical Association 281 (1999) 1598-1604
56. Koutsilieris M., Faure N., Tolis G., et al. Objective response and disease outcome in 59 patients with stage D2 prostatic cancer treated with either Buserelin or orchiectomy. Disease aggressivity and its association with response and outcome. Urology 27 (1986) 221-228
57. Koutsilieris M., and Tolis G. Long-term follow-up of patients with advanced prostatic carcinoma treated with either buserelin (HOE 766) or orchiectomy: classification of variables associated with disease outcome. The Prostate 7 (1985) 31-39
58. Koutsilieris M., Tenta R., Tiblalexi D., et al. Bone metastasis microenvironment participates in the development of androgen ablation refractoriness and chemotherapy resistance of prostate cancer cells residing in the skeleton: clinical implications. In: Meadows G. (Ed). Integration/interaction of oncologic growth (2005), Springer 335-344
59. Pantel K., Cote R.J., and Fodstad O. Detection and clinical importance of micrometastatic disease. Journal of the National Cancer Institute 91 (1999) 1113-1124
60. Athanassiadou P., and Grapsa D. Recent advances in the detection of bone marrow micrometastases: A promising area for research or just another false hope? A review of the literature. Cancer Metastasis Reviews 25 (2006) 507-519
61. Sourla A., Lembessis P., Mitsiades C., et al. Conversion of nested reverse-transcriptase polymerase chain reaction from positive to negative status at peripheral blood during androgen ablation therapy is associated with long progression-free survival in stage D2 prostate cancer patients. Anticancer Research 21 (2001) 3565-3570
62. Lembessis P., Msaouel P., and Halapas A. Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy. Clinical Chemistry and Laboratory Medicine 45 (2007) 1488-1494
63. Lembessis P., Sourla A., Mitsiades C., et al. Molecular staging in clinically localized and advanced prostate cancer. In: Labrie F., and Koutsilieris M. (Eds). Prostate cancer: understanding the pathophysiology and re-designing a therapeutic approach (2004), Paschalidis Medical Publications, Athens 97-107
64. Mitropapas G., Nezos A., Halapas A., et al. Molecular detection of tyrosinase transcripts in peripheral blood from patients with malignant melanoma: correlation of PCR sensitivity threshold with clinical and pathologic disease characteristics. Clinical Chemistry and Laboratory Medicine 44 (2006) 1403-1409
65. de Cremoux P., Ravery V., Podgorniak M.P., et al. Value of the preoperative detection of prostate-specific-antigen-positive circulating cells by nested RT-PCR in patients submitted to radical prostatectomy. European Urology 32 (1997) 69-74
66. Lintula S., and Stenman U.H. The expression of prostate-specific membrane antigen in peripheral blood leukocytes. The Journal of Urology 157 (1997) 1969-1972
67. Loric S., Dumas F., Eschwege P., et al. Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse transcription polymerase chain reaction assay based on prostate-specific membrane antigen. Clinical Chemistry 41 (1995) 1698-1704
68. Koutsilieris M., Reyes-Moreno C., Sourla A., et al. Growth factors mediate glucocorticoid receptor function and dexamethasone-induced regression of osteoblastic lesions in hormone refractory prostate cancer. Anticancer Research 17 (1997) 1461-1465
69. Kruit A., Reyes-Moreno C., Newling D.W., et al. Response of PC-3 prostate cancer cells to combination therapy using irradiation with glucocorticoids or doxorubicin. Anticancer Research 19 (1999) 3153-3156
70. Reyes-Moreno C., and Koutsilieris M. Glucocorticoid receptor function possibly modulates cell-cell interactions in osteoblastic metastases on rat skeleton. Clinical & Experimental Metastasis 15 (1997) 205-217
71. Koutsilieris M., Dimopoulos T., Milathianakis C., et al. Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis. BJU International 100 Suppl. 2 (2007) 60-62
72. Msaouel P., Diamanti E., Tzanela M., et al. Luteinising hormone-releasing hormone antagonists in prostate cancer therapy. Expert Opinion on Emerging Drugs 12 (2007) 285-299
73. Davies P.H., Stewart S.E., Lancranjan L., et al. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clinical Endocrinology 48 (1998) 311-316
74. Dimopoulos M.A., Kiamouris C., Gika D., et al. Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study. Urology 63 (2004) 120-125
75. Koutsilieris M., Mitsiades C., Dimopoulos T., et al. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients. The Journal of Clinical Endocrinology and Metabolism 86 (2001) 5729-5736
76. Mitsiades C.S., Bogdanos J., Karamanolakis D., et al. Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer. Anticancer Research 26 (2006) 3693-3700